Ondine Biomedical Inc. (AIM: OBI)
London
· Delayed Price · Currency is GBP · Price in GBX8.06
-0.44 (-5.15%)
Nov 19, 2024, 9:17 AM GMT+1
Ondine Biomedical Income Statement
Financials in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2010 | 2009 - 2005 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '10 Dec 31, 2010 | 2009 - 2005 |
| Revenue | 1.63 | 1.2 | 0.64 | 2.57 | 1.79 | 1.53 | Upgrade
|
| Revenue Growth (YoY) | 103.23% | 88.56% | -75.17% | 43.44% | 16.84% | 48.79% | Upgrade
|
| Cost of Revenue | 0.65 | 0.5 | 0.35 | 1.32 | 1.14 | 0.26 | Upgrade
|
| Gross Profit | 0.98 | 0.7 | 0.29 | 1.25 | 0.65 | 1.28 | Upgrade
|
| Selling, General & Admin | 8.78 | 9.8 | 12.31 | 13.33 | 12.04 | 1.91 | Upgrade
|
| Research & Development | 6.26 | 5.14 | 6.28 | 4.98 | 3.31 | 3.25 | Upgrade
|
| Operating Expenses | 15.59 | 15.51 | 19.05 | 18.77 | 16.52 | 5.46 | Upgrade
|
| Operating Income | -14.61 | -14.81 | -18.76 | -17.52 | -15.87 | -4.18 | Upgrade
|
| Interest Expense | -0.06 | -0.05 | -0.03 | -0.01 | -0.49 | - | Upgrade
|
| Interest & Investment Income | 0.04 | 0.24 | 0.19 | - | - | 0.02 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | -0.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.06 | -0.14 | 0.64 | 0.19 | 0.14 | 0.03 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.13 | 0 | -1.33 | -1.63 | -0.05 | 0.25 | Upgrade
|
| EBT Excluding Unusual Items | -14.56 | -14.75 | -19.29 | -18.98 | -16.27 | -3.9 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | -0.1 | -0.08 | - | - | 0.58 | Upgrade
|
| Other Unusual Items | 0.29 | 0.44 | - | -31.11 | - | 0.05 | Upgrade
|
| Pretax Income | -14.27 | -14.41 | -19.37 | -50.09 | -16.27 | -3.27 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | -0.01 | Upgrade
|
| Net Income | -14.27 | -14.41 | -19.37 | -50.09 | -16.27 | -3.26 | Upgrade
|
| Net Income to Common | -14.27 | -14.41 | -19.37 | -50.09 | -16.27 | -3.26 | Upgrade
|
| Shares Outstanding (Basic) | 220 | 197 | 195 | 80 | 71 | 8 | Upgrade
|
| Shares Outstanding (Diluted) | 220 | 197 | 195 | 80 | 71 | 8 | Upgrade
|
| Shares Change (YoY) | 13.24% | 1.30% | 144.34% | 12.69% | 761.95% | 48.67% | Upgrade
|
| EPS (Basic) | -0.06 | -0.07 | -0.10 | -0.63 | -0.23 | -0.40 | Upgrade
|
| EPS (Diluted) | -0.06 | -0.07 | -0.10 | -0.63 | -0.23 | -0.40 | Upgrade
|
| Free Cash Flow | -12.58 | -13.83 | -16.66 | -12.62 | -6.36 | -2.9 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.07 | -0.09 | -0.16 | -0.09 | -0.35 | Upgrade
|
| Gross Margin | 60.04% | 58.44% | 44.98% | 48.81% | 36.24% | 83.36% | Upgrade
|
| Operating Margin | -893.82% | -1230.67% | -2940.91% | -681.98% | -886.15% | -272.72% | Upgrade
|
| Profit Margin | -873.56% | -1198.00% | -3036.36% | -1949.59% | -908.49% | -212.47% | Upgrade
|
| Free Cash Flow Margin | -769.65% | -1149.63% | -2610.66% | -491.12% | -355.00% | -189.20% | Upgrade
|
| EBITDA | -14.42 | -14.59 | -18.54 | -17.24 | -14.91 | -3.88 | Upgrade
|
| EBITDA Margin | - | - | - | - | - | -253.26% | Upgrade
|
| D&A For EBITDA | 0.19 | 0.21 | 0.22 | 0.28 | 0.96 | 0.3 | Upgrade
|
| EBIT | -14.61 | -14.81 | -18.76 | -17.52 | -15.87 | -4.18 | Upgrade
|
| EBIT Margin | - | - | - | - | - | -272.72% | Upgrade
|
| Advertising Expenses | - | 0.18 | 0.23 | 0.14 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.